Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorundrostat SCHEMBL18489931 | 1.00 | CYP11B2 (1.00) | CYP11B2 | |
| Lorundrostat SCHEMBL29501060 | 1.00 | CYP11B2 (1.00) | CYP11B2 | |
| Lorundrostat SCHEMBL29536765 | 0.99 | CYP11B2 (0.98) | CYP11B2 | |
| Lorundrostat SCHEMBL25323630 | 0.99 | CYP11B2 (0.98) | CYP11B2 | |
| Lorundrostat SCHEMBL25323633 | 0.99 | CYP11B2 (0.98) | CYP11B2 | |
| SCHEMBL27132479 | 0.91 | CYP11B2 (0.84) | CYP11B2 | |
| SCHEMBL18489903 | 0.90 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL18502893 | 0.87 | CYP11B2 (0.76) | CYP11B2 | |
| SCHEMBL18489968 | 0.86 | CYP11B2 (0.84) | CYP11B2 | |
| SCHEMBL28557913 | 0.86 | CYP11B2 (0.84) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008756-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-08 | — | — | US | claimed |
| EP-4623917-A2 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-10-01 | — | — | EP | claimed |
| CN-117957213-A | Soluble pharmaceutical compositions comprising salts of disubstituted 1,2, 4-triazine compounds | 矿物疗法公司 | 2024-04-30 | — | — | CN | claimed |
| US-20230365513-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | claimed |
| EP-4215244-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-07-26 | — | — | EP | claimed |
| CN-116323569-A | Salts of triazine compounds, crystalline forms thereof, and methods of manufacture | 田边三菱制药株式会社 | 2023-06-23 | — | — | CN | claimed |
| CN-106232587-B | Disubstituted 1,2, 4-triazine compounds | 田边三菱制药株式会社 | 2021-04-13 | — | — | CN | claimed |
| US-20260008756-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-08 | — | — | US | disclosed |
| US-20260008756-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-08 | — | — | US | disclosed |
| EP-4623917-A3 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4623917-A2 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4623917-A2 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-10-01 | — | — | EP | disclosed |
| CN-117957213-A | Soluble pharmaceutical compositions comprising salts of disubstituted 1,2, 4-triazine compounds | 矿物疗法公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230365513-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230365513-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-4215244-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215244-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116323569-A | Salts of triazine compounds, crystalline forms thereof, and methods of manufacture | 田边三菱制药株式会社 | 2023-06-23 | — | — | CN | disclosed |
| CN-116323569-A | Salts of triazine compounds, crystalline forms thereof, and methods of manufacture | 田边三菱制药株式会社 | 2023-06-23 | — | — | CN | disclosed |
| CN-106232587-B | Disubstituted 1,2, 4-triazine compounds | 田边三菱制药株式会社 | 2021-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365513-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | REN, STS, HSD11B1 | CYP11B2 10/4885 |
| US-20260008756-A1 | TRIAZINE COMPOUND SALT, CRYSTAL FORM THEREOF, AND PRODUCTION METHOD THEREFOR | REN, HSD11B2, HSD11B1 | CYP11B2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.